Somite AI Raises $47M Series A to Revolutionize AI-Driven Cell Therapies

We are thrilled to announce that Somite.ai has successfully raised $47 million in its latest funding round, marking a pivotal milestone in our mission to revolutionize cell therapy through the power of artificial intelligence. Somite.ai is at the forefront of developing AI foundation models for human stem cells, employing a full-stack approach that not only generates high-quality data at 1,000x lower cost, but also trains large-scale models with unmatched predictive power. These innovative models are key to discovering, refining, and optimizing high-impact applications in cell therapy, ultimately paving the way for novel treatments and improved patient outcomes. This significant injection of capital will accelerate our efforts to advance the field of regenerative medicine by scaling our operations and refining our proprietary technologies. With the funding, we plan to expand our research and development teams, enhance our data generation processes, and push the boundaries of AI-driven discovery in cell therapy applications. Our founding team, led by repeat AI entrepreneur Dr. Micha Breakstone, and complemented by the esteemed Head of the Fundamental AI Group at MIT along with four Harvard Medical School professors and National Academy of Sciences/Medicine members, provides an unrivaled combination of expertise in AI and cutting-edge biomedical research. Based in Boston and gearing up for our launch in January 2024, Somite.ai is poised to redefine how cell therapies are developed and brought to market. This funding round not only reflects robust investor confidence in our vision and technology but also empowers us to bring transformative treatments to more patients in need, solidifying our role as a leader at the nexus of artificial intelligence and modern medicine.